IFNA1 and neoplasm: STING acts through two main pathways: (1) upregulation of type I interferon (IFN) release by activating IRF3 and by activating NF-κB, mainly by tumour infiltrating CD141+ dendritic cells, a subtype specialised in antigen cross-presentation [15].